This protocol describes an open-label randomized controlled trial (EAGISM) to assess the efficacy and safety of electroacupuncture (EA) as an adjunctive therapy for the prevention of septic acute gastrointestinal injury (S-AGI) in patients with sepsis. The study will take place in a Chinese hospital in Guvinciang province and will involve a total of 200 mechanically ventilated patients aged 18 years and older with a clinical diagnosis of sepsis. Patients will be randomly assigned 1:1 to the EA group (combination of EA and conventional drug therapy) or the control group (only conventional drug therapy for S-AGI). Blinding will only be for blood test assessors and statisticians. The primary endpoint is the incidence of S-AGI on day 10. Secondary endpoints include S-AGI severity, gastric retention, abdominal girth, intra-abdominal pressure, frequency of bowel sounds, number of days tolerating daily feeding goal, proportion of patients receiving erythromycin or metoclopramide for feeding intolerance, prealbumin levels, incidence of persistent inflammation, immunosuppression and catabolism syndrome (PICS), number of days on invasive mechanical ventilation, length of ICU stay, 7-day and 28-day mortality and adverse events. The study is registered under the identifier ChiCTR2300078141.